NEW YORK, August 5, 2026, 13:05 EDT — Shares of Geron NASDAQ:GERN advanced after Rytelo sales edged closer to the company’s guidance midpoint.
- Geron gained 18.3% to $1.585 in early Nasdaq trade.
- Rytelo revenue for the second quarter rose 11% from the previous quarter, reaching $57.5 million.
- The lower end of the guidance now implies just 1.4% growth in the second half compared to the first half.
Shares of Geron rose on Wednesday, as Rytelo sales continued to climb for another quarter. At the current rate, second-quarter sales would annualize at $229.9 million, aligning closely with the midpoint of Geron’s 2026 revenue forecast.
The figures outweigh the flat guidance. Product revenue in the first six months totaled $109.2 million. To achieve $220 million, Geron must generate $110.8 million in the latter half. That target remains modest.
During the earnings call, management struck a more optimistic note. The company is now projecting Rytelo revenue to land in the mid-to-upper range of its earlier guidance. Chief Financial Officer Michelle Robertson also outlined expectations for “consistent quarter-over-quarter net revenue growth throughout the year.” Yahoo Finance
What Geron’s revised full-year outlook demands
| 2026 Rytelo target | Required H2 revenue | H2 growth over H1 | Needed quarterly average | Compared to Q2 run rate |
|---|---|---|---|---|
| $220 million | $110.8 million | +1.4% | $55.4 million | -3.6% |
| $230 million midpoint | $120.8 million | +10.5% | $60.4 million | +5.1% |
| $240 million | $130.8 million | +19.7% | $65.4 million | +13.8% |
The figures are based on disclosed first-half product revenue of $109.244 million and product revenue from the second quarter of $57.473 million.
Several indicators showed stronger commercial momentum. Rytelo revenue increased 11% over the previous quarter and climbed 17% from a year ago. Demand grew 5%, with ordering accounts up by around 8% to approximately 1,575. Chief Executive Harout Semerjian described it as a “third consecutive quarter of RYTELO demand growth.” Geron Corporation
Q2 commercial performance overview
| Metric | Q2 2026 | Comparison | Reported change |
|---|---|---|---|
| Rytelo net product revenue | $57.5 million | $51.8 million in Q1 | Up 11% |
| Rytelo net product revenue | $57.5 million | $49.0 million in Q2 2025 | Up 17% |
| Demand volume | Not disclosed | Q1 2026 | Up 5% |
| Ordering accounts | Approximately 1,575 | Q1 2026 | Increase of about 8% |
| Cash and securities | $326.9 million | $341.0 million in Q1 | Down 4.1% |
All figures from company; cash movement based on stated balances.
Revenue increased at over double the pace of stated demand, indicating factors such as mix, pricing, or channel timing also contributed to sales. Management stated that distributor inventory was held at between two and four weeks. The company does not anticipate significant inventory fluctuations in the remainder of the year.
Profit gains lagged behind. Costs and operating expenses increased to $70.0 million, up from $61.5 million. Geron largely attributed this to non-cash inventory-related charges. The company posted a quarterly loss of two cents per share, wider than FactSet’s forecast for a one-cent loss.
Cost breakdown
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Total revenue | $57.48 million | $49.04 million | +17.2% |
| Cost of goods sold | $9.24 million | $1.19 million | +676.5% |
| Research and development | $22.03 million | $21.74 million | +1.4% |
| Selling, general and administrative | $38.86 million | $38.56 million | +0.8% |
| Operating loss | $12.50 million | $12.45 million | Little changed |
Adjustments are based on Geron’s unaudited quarterly financial report.
Cash and securities dropped by $14.1 million over the quarter. Geron stated that current resources along with anticipated U.S. sales are expected to support operations for the foreseeable future. Non-COGS operating expenses in the first half decreased by 4%, as revenue rose around 24%.
Rytelo is a competitor to Bristol Myers Squibb’s NYSE:BMY Reblozyl in the lower-risk myelodysplastic syndromes space. The surge in Geron shares notably outpaced broader biotech sector gains. Trading volume hit 21.1 million shares, approximately 1.65 times the stock’s 65-day average.
Market overview
| Security | Relevance | Price | Session change |
|---|---|---|---|
| Geron NASDAQ:GERN | Maker of Rytelo | $1.585 | +18.3% |
| Bristol Myers Squibb NYSE:BMY | Holder of Reblozyl | $63.57 | -3.5% |
| SPDR S&P Biotech ETF (NYSEARCA:XBI) | Benchmark for biotech sector | $152.90 | +0.7% |
| iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) | Index for large-cap biotech | $191.68 | +0.8% |
Most recent prices as of approximately 12:50 p.m. EDT. Movements among peers could be due to unrelated news affecting those companies.
Sustained value continues to depend on broadening clinical use. Geron projects around 8,000 second-line patients in the U.S. could be reached. The company intends to present its European commercial approach before the end of the year. An interim survival analysis for IMpactMF is expected in the second half of 2026, followed by a final review in the latter half of 2028.
FactSet data shows four analysts rate the stock a Buy and one rates it a Hold, with no Sells. The mean price target stands at $4.00, suggesting potential gains of approximately 152% from the most recent share price.
Analyst ratings
| Measure | Current reading |
|---|---|
| Buy recommendations | 4 |
| Hold recommendations | 1 |
| Sell recommendations | 0 |
| Analyst consensus | Buy |
| Mean price target | $4.00 |
| Target price range | $3.00-$5.00 |
| Potential gain to mean target | About 152% |
FactSet provides recommendation and target figures; the implied upside is based on $1.585.
Risks: Rytelo continues to be Geron’s main commercial product. Gross-to-net deductions increased to 20.7%, up from 15.3% in the previous year. Meeting the upper end of guidance requires quarterly sales to be 13.8% higher than in Q2. Factors such as slower adoption, pricing pressure in Europe, or postponed IMpactMF results could impact valuation.
The upcoming test is straightforward. Third-quarter revenue needs to top $57.5 million in order to meet management’s forecast for sequential growth. Maintaining the midpoint trend requires about $60 million. More is necessary to reach the upper target.
